Ra-dichloride is an alpha-emitting radiopharmaceutical used in the treatment of bone metastases from castration-resistant prostate cancer. Image-based dosimetric studies remain challenging because the emitted photons are few. The aim of this study was to implement a methodology for in-vivo quantitative planar imaging, and to assess the absorbed dose to lesions using the MIRD approach.
Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride / Pacilio, Massimiliano; Ventroni, Guido; DE VINCENTIS, Giuseppe; Cassano, Bartolomeo; Pellegrini, Rosanna; DI CASTRO, Elisabetta; Frantellizzi, Viviana; Follacchio, GIULIA ANNA; Garkavaya, Tatiana; Lorenzon, Leda; Ialongo, Pasquale; Pani, Roberto; Mango, Lucio. - In: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. - ISSN 1619-7070. - STAMPA. - 43:1(2016), pp. 21-33. [10.1007/s00259-015-3150-2]
Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride
DE VINCENTIS, Giuseppe;PELLEGRINI, Rosanna;DI CASTRO, Elisabetta;FRANTELLIZZI, VIVIANA;FOLLACCHIO, GIULIA ANNA;GARKAVAYA, TATIANA;LORENZON, LEDA;IALONGO, PASQUALE;PANI, Roberto;MANGO, Lucio
2016
Abstract
Ra-dichloride is an alpha-emitting radiopharmaceutical used in the treatment of bone metastases from castration-resistant prostate cancer. Image-based dosimetric studies remain challenging because the emitted photons are few. The aim of this study was to implement a methodology for in-vivo quantitative planar imaging, and to assess the absorbed dose to lesions using the MIRD approach.| File | Dimensione | Formato | |
|---|---|---|---|
|
Pacilio_Dosimetry_2016.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.03 MB
Formato
Adobe PDF
|
1.03 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
